{"pmid":32301221,"title":"A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity.","text":["A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity.","A preliminary observation of high frequency of male pattern hair loss among admitted COVID-19 patients, and suggest that androgen expression might be a clue to COVID-19 severity.","J Cosmet Dermatol","Goren, A","Vano-Galvan, S","Wambier, C G","McCoy, J","Gomez-Zubiaur, A","Moreno-Arrones, O M","Shapiro, J","Sinclair, R","Gold, M H","Kovacevic, M","Mesinkovska, N A","Goldust, M","Washeni, K","32301221"],"abstract":["A preliminary observation of high frequency of male pattern hair loss among admitted COVID-19 patients, and suggest that androgen expression might be a clue to COVID-19 severity."],"journal":"J Cosmet Dermatol","authors":["Goren, A","Vano-Galvan, S","Wambier, C G","McCoy, J","Gomez-Zubiaur, A","Moreno-Arrones, O M","Shapiro, J","Sinclair, R","Gold, M H","Kovacevic, M","Mesinkovska, N A","Goldust, M","Washeni, K"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301221","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jocd.13443","keywords":["5-alpha reductase","ace2","angiotensin converting enzyme 2","covid-19","cannabidiol","dutasteride","enzalutamide","finasteride","sars-cov-2","tmprss2","androgen receptor","androgenetic alopecia","anti-androgen therapy","human skin","retinoids","transmembrane protease serine 2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"_version_":1664357978580451330,"score":8.233237,"similar":[{"pmid":32283245,"pmcid":"PMC7151476","title":"SARS-COV-2 infection is likely to be androgen mediated.","text":["SARS-COV-2 infection is likely to be androgen mediated.","J Am Acad Dermatol","Wambier, Carlos Gustavo","Goren, Andy","32283245"],"journal":"J Am Acad Dermatol","authors":["Wambier, Carlos Gustavo","Goren, Andy"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283245","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.04.032","keywords":["5-alpha reductase","ACE2","Angiotensin Converting Enzyme 2","COVID-19","SARS-CoV-2","TMPRSS2","androgen receptor","androgenetic alopecia","anti-androgen therapy","dutasteride","finasteride","human skin","retinoids","transmembrane protease serine 2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664182200820563969,"score":362.37103},{"pmid":32303424,"title":"Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","text":["Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19.","J Autoimmun","Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher","32303424"],"abstract":["It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19."],"journal":"J Autoimmun","authors":["Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303424","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaut.2020.102463","keywords":["2019-ncov","ace2","covid-19","immune response","protein-protein interactions","sars-cov-2","susceptibility"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664431720451014656,"score":102.71577},{"pmid":32304747,"title":"Angiotensin Receptor Blockers and 2019-nCoV.","text":["Angiotensin Receptor Blockers and 2019-nCoV.","Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients.","Pharmacol Res","Saavedra, Juan M","32304747"],"abstract":["Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients."],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304747","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104832","keywords":["ace2","angiotensin receptor blockers","covid-19","sars-cov-2","coronavirus"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664431720484569090,"score":73.18102},{"pmid":32269893,"pmcid":"PMC7138423","title":"A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).","text":["A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.","Cureus","Kakodkar, Pramath","Kaka, Nagham","Baig, M N","32269893"],"abstract":["Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic."],"journal":"Cureus","authors":["Kakodkar, Pramath","Kaka, Nagham","Baig, M N"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32269893","week":"202015|Apr 06 - Apr 12","doi":"10.7759/cureus.7560","keywords":["ace2","ards","chloroquine","covid-19","lopinavir and ritonavir","mrna-1273 vaccine","pandemic","remdesivir (gs-5734)","sars-cov-2","severe acute respiratory infection"],"source":"PubMed","locations":["COVID19"],"topics":["Treatment","Diagnosis"],"weight":1,"e_drugs":["Ibuprofen","Ascorbic Acid","Vitamin D"],"_version_":1663620083064242178,"score":65.77587},{"pmid":32271490,"title":"A primer on viral-associated olfactory loss in the era of COVID-19.","text":["A primer on viral-associated olfactory loss in the era of COVID-19.","Early reports have suggested that smell loss may be an early symptom associated with the pandemic known as COVID-19. The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might cause olfactory dysfunction is certainly plausible. Patients presenting to specialized smell clinics are commonly diagnosed with upper respiratory infection (URI)-associated olfactory loss and most are presumed to be viral related. In acute phases of infection, it is common to experience some smell loss as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. In most cases, these episodes of smell loss are self-limiting and coincide with resolution of URI symptoms. However, in some cases the smell loss persists for months to years and this is presumed to occur through a more direct olfactory insult by the virus. It remains too early to know whether infection with SARS-CoV-2 causes persistent olfactory dysfunction. However, given the scale of this pandemic, if SARS-CoV-2 does cause chronic olfactory loss in even a small portion of those infected, then the overall population prevalence could be quite large. This review provides a brief, practical overview of viral-associated olfactory loss, realizing that evidence related to COVID-19 will likely not be clear for some time. Our goal is to highlight the existence and importance of this condition and provide information geared for both providers and patients. Practical suggestions regarding evaluation and treatment will be provided, realizing that there may be constraints on medical resources and the nature of this pandemic remains dynamic. This article is protected by copyright. All rights reserved.","Int Forum Allergy Rhinol","Soler, Zachary M","Patel, Zara M","Turner, Justin H","Holbrook, Eric H","32271490"],"abstract":["Early reports have suggested that smell loss may be an early symptom associated with the pandemic known as COVID-19. The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might cause olfactory dysfunction is certainly plausible. Patients presenting to specialized smell clinics are commonly diagnosed with upper respiratory infection (URI)-associated olfactory loss and most are presumed to be viral related. In acute phases of infection, it is common to experience some smell loss as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. In most cases, these episodes of smell loss are self-limiting and coincide with resolution of URI symptoms. However, in some cases the smell loss persists for months to years and this is presumed to occur through a more direct olfactory insult by the virus. It remains too early to know whether infection with SARS-CoV-2 causes persistent olfactory dysfunction. However, given the scale of this pandemic, if SARS-CoV-2 does cause chronic olfactory loss in even a small portion of those infected, then the overall population prevalence could be quite large. This review provides a brief, practical overview of viral-associated olfactory loss, realizing that evidence related to COVID-19 will likely not be clear for some time. Our goal is to highlight the existence and importance of this condition and provide information geared for both providers and patients. Practical suggestions regarding evaluation and treatment will be provided, realizing that there may be constraints on medical resources and the nature of this pandemic remains dynamic. This article is protected by copyright. All rights reserved."],"journal":"Int Forum Allergy Rhinol","authors":["Soler, Zachary M","Patel, Zara M","Turner, Justin H","Holbrook, Eric H"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271490","week":"202015|Apr 06 - Apr 12","doi":"10.1002/alr.22578","keywords":["coronavirus, smell","olfaction","post-viral","upper respiratory infection"],"source":"PubMed","topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1663620083129253889,"score":65.617744}]}